We evaluated predictive value of left ventricular ejection fraction at rest (REF) and its increment with exercise (⌬EF) on autologous and allogeneic stem cell transplantation mortality. In a 7 year period, a total of 163 patients evaluated for stem cell transplantation were studied. All were followed for at least 3 months after the transplant. REF was discriminatory for peritransplant mortality only in younger (Ͻ43 years) patients (n ‫؍‬ 66), particularly those who underwent autologous transplantation (n ‫؍‬ 30). Resting ejection fraction was not a discriminator for early death in any other subgroup. Cardiac reserve (⌬EF) was significantly lower in patients (n ‫؍‬ 35), who died early. The finding was most prominent in younger patients who underwent autologous transplantation (n ‫؍‬ 26). Combination of decreased REF and low ⌬EF (n ‫؍‬ 18) was associated with high peritransplant mortality (56%), after both autologous and allogeneic transplantation. A low REF with an appropriate ⌬EF (n ‫؍‬ 43) was associated with a 19% peritransplant mortality and no deaths in the autologous group. These observations indicate that resting ejection fraction is of only limited value for pretransplant evaluation. However, measurement of cardiac reserve during exercise can provide important prognostic information before stem cell transplantation.
The cardiovascular system has long been considered to be relatively radio-resistant and not a major target of chemotherapy toxicity. However, with more successful outcomes of cancer treatment, a greater proportion of longer survivors show long-term effects of these treatment modalities. The best known and described cardiovascular culprits are highdose radiation for mediastinal lymphoma, 1,2 the use of anthracyclines 3 and high doses of cyclophosphamide, often included in preparative regimens for bone marrow transplantation. 4, 5 Stem cell transplantation can cure a variety of benign and malignant hematological diseases, and has also been used to treat solid organ tumors. Nevertheless, peritransplant morbidity and mortality remain considerable. Assessment of organ functions is commonly utilized to determine transplant protocol eligibility, but the validity of these potentially restrictive criteria has not been fully established. In addition, as the upper age limit increases and older patients are considered transplant candidates, the importance of cardiovascular evaluation will become critical. For evaluation of the cardiovascular system, measurement of the left ventricular ejection fraction (REF) is by far the most commonly used parameter. Decisions are frequently made to adjust or withhold chemotherapy based on these studies. Patients with significant baseline cardiac dysfunction are often not considered for dose-intensive therapy, even if the prognostic value of pretransplant cardiac evaluation has not been clearly defined. Thus, it may not be justified to use arbitrary cut-off values to exclude patients from receiving this potentially life-saving procedure. In addition, it is unknown whether the use of cardiac testing in the setting of stem cell transplantation is cost-effective.
The purpose of this study was to evaluate the predictive value of the left ventricular ejection fraction at rest and during exercise by gated blood pool studies on overall peritransplant mortality.
Patients and methods
We reviewed the results of gated blood pool imaging at rest and with exercise in all patients referred for evaluation from January 1990 to May 1997 at The Mount Sinai Medical Center in New York. Out of a total of 240 patients referred, 174 subsequently underwent stem cell transplantation. Three patients were excluded from the analysis because of the poor quality of the images, along with eight patients who were too ill at the time of evaluation to exercise, and therefore only had gated blood studies at rest. A total of 163 patients (60 male, 103 female) were included; their mean age was 43 ± 11 years (13-69 years). Mean age of patients who received allogeneic transplant was lower than of those who received autologous transplant: 38 ± 12 vs 45 ± 10 years, P = 0.0001. Average time from gated blood pool imaging to transplantation was 46 ± 19 days. The diagnoses, type of transplantation and preparatory regimens are depicted in Table 1 . All patients were followed in our clinic for a minimum of 3 months after transplantation. No patient was lost to follow-up. Anthra = previous therapy with anthracycline; Auto = autologous; Allo = allogeneic transplantation; CML = chronic myelocytic leukemia; AML = acute myelocytic leukemia; Waldenstrom's = Waldenstrom's macroglobulinemia; RAEB/RAEBT = refractory anemia with excessive blasts/refractory anemia with excessive blasts in transformation.
Gated blood pool imaging was performed at rest and during exercise. Patient red blood cells were labeled in vivo with 20-25 mCi of Tc 99m pertechnetate 15-20 min after 1.5 ml injection of stannous pyrophosphate. Multigated equilibrium scintigraphy was performed at rest in the anterior, left anterior oblique and left lateral position in a 64 × 64 matrix using 16 frames for 5 min. Left anterior oblique acquisition was repeated at the peak of symptom limited supine bicycle exercise. The ventricular ejection fraction at rest (REF) and at peak exercise (ExEF) were measured in duplicates from the rest and peak exercise acquisitions using commercial software. REF у50% was considered normal. Left ventricular ejection fraction increase (⌬EF), or cardiac reserve (⌬EF = ExEF − REF), by у5% during exercise was considered adequate. Continuous variables are expressed as mean ± s.d. Standard t-tests and 2 tests were used for statistical comparisons. P value of Ͻ0.05 was considered significant.
Results
Thirty-five of the 163 patients (21%) died within 3 months of stem cell transplantation. The causes of death were multi-organ failure in eight, infection in seven, pulmonary complications in seven, bleeding complications in five, primary disease relapse in three, hepatic complications in two, graft-versus-host disease in one patient. Cause of death was not determined in two patients. No deaths were attributed to congestive heart failure. Mortality was higher in patients who received allogeneic transplants (22/57, 39%), compared to those who received autologous transplants (13/106, 12%).
Left ventricular ejection at rest (REF) of the whole group was 52 ± 8% (23-71%). REF was abnormal (Ͻ50%) in 61 patients (37%). Patients who expired within 3 months after transplantation (n = 35) had similar REF when compared to the survivors (n = 128): 50 ± 8% vs 52 ± 8%, P = NS. Among the 66 patients younger than the mean age of the group (Ͻ43 years), peritransplant mortality was higher in those with abnormal REF (eight of 24 patients vs five of 42 patients, P Ͻ 0.05). This was even more prominent in the 30 younger patients who received autologous transplants (four of 10, and none of 20 patients, respectively, P Ͻ 0.02). Death in the older population (n = 97) did not correlate with pretransplant REF.
The mean ⌬EF (cardiac reserve) of the whole group was 8 ± 6%, and it was abnormal (Ͻ5%) in 44 patients (27%). Cardiac reserve was lower in patients who died early compared to their counterparts (Table 2 ): 6 ± 5% vs 9 ± 6% (P = 0.03). Younger patients (Ͻ43 years) with low ⌬EF demonstrated a mortality of 44% (seven of 16 patients) compared to 15% (seven of 50 patients) in patients with adequate cardiac reserve (P Ͻ 0.01). Among younger patients, no deaths were recorded in the autologous group with adequate ⌬EF (n = 26 patients), compared to the 50% (four of eight patients) among patients with low ⌬EF (P Ͻ 0.01).
Analysis of the group by both REF and ⌬EF is summar- 
Discussion
Fatal cardiac toxicity in patients receiving bone marrow transplants has been shown to vary from less than 1, to 9%. 6, 7, 8 Even if high-dose cyclophosphamide-induced cardiac toxicity has not been clearly related to another factor such as previous dose of anthracycline therapy or the use of radiation, both have been considered as cofactors for cardiac toxicity. 9 Identification of patients with early stages of cardiac dysfunction is used for selection of chemotherapeutic agents included in preparative regimens and/or for use of agents which can prevent further deterioration of myocardial function. In an attempt to identify reliable pretransplant parameters, prospective trials have analyzed sensitivity of serial echocardiograms and electrocardiograms after cyclophosphamide administration. 8 These studies were not able to demonstrate a correlation between decrease in ECG voltage, increase in left ventricular mass index and clinical cardiotoxicity. More recently, positron emission tomography scans obtained before and after cyclophosphamide administration failed to show any prognostic value. 10 Compared to the nontransplanted patients, a surprisingly low incidence of cardiac deaths have been reported by several groups after stem cell transplantation. Cardiac toxicity was seen in only seven out of 136 patients reported by Bearman et al 11 and only eight out of 170 patients who underwent bone marrow transplantation as reported by Hertenstein et al. 12 These observations have led some groups to recommend evaluation of myocardial function only in patients with a clinical history or physical evidence of cardiac disease. Also, some authors have suggested that patients with subclinical cardiovascular impairment should not be excluded from bone marrow transplantation. 13 Our study confirms poor predictive value of pretransplant evaluation for cardiac death. None of our patients is known to have died of congestive heart failure. However, a selection bias in this cohort is likely. Mean LVEF for the group was high at 52%. Patients with low baseline LVEF were not considered for stem cell transplantation.
Measurement of cardiac reserve during exercise appeared Our study is the first to show a prognostic value for exercise ejection fraction in the pretransplantation setting. Prospective studies are needed to confirm our preliminary observations and to evaluate the role of possible early interventions (such as pretreatment with angiotensin converting enzyme inhibitors or betablockers) for improvement of early survival after stem cell transplantation. 13, 14 
